Tempus AI (TEM 21. 73%), a niche artificial intelligence (AI) company, recently went public and is making significant strides in the market. After news broke about its strategic investment in a fellow company, investors pushed Tempus AI's stock up by nearly 22% on Wednesday, surpassing the S&P 500 index's 0. 4% gain for the day. In a regulatory filing released after market hours on Tuesday, Tempus AI disclosed its recent acquisition of shares from Personalis (PSNL 11. 42%) as part of their investment agreement. Both companies had announced this arrangement at the end of last week. Tempus AI exercised two sets of warrants, which it acquired in late 2023, to purchase just over 9. 2 million Personalis shares at prices ranging from $1. 50 to $2. 50 per share.

This exercise amounted to a total cost of slightly over $18. 4 million. Additionally, Tempus AI directly bought 3. 5 million shares from Personalis at $5. 07 per share, accounting for a total of over $17. 7 million. These two companies have substantial synergy as Tempus AI specializes in healthcare "intelligence diagnostics" while Personalis is a biotech firm renowned for its development of cancer diagnostic tests. Their 2023 strategic collaboration aimed to commercialize Personalis' NeXT Personal Dx diagnostic product. Currently, Tempus AI owns just over 19% of Personalis' outstanding common shares, as confirmed by both companies.